Athira Pharma presented new clinical and preclinical data further highlighting the therapeutic potential of fosgonimeton at the AD/PD 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders, being held in Lisbon, Portugal March 5 – 9, 2024. “Data presented at AD/PD, in tandem with the existing body of preclinical and clinical evidence, continue to support the potential of targeting the neurotrophic HGF system to treat neurodegenerative diseases, including Parkinson’s disease, Alzheimer’s disease and dementia with Lewy bodies,” said Mark Litton, Ph.D., President and Chief Executive Officer of Athira. “We believe safety and efficacy outcomes from the exploratory SHAPE Phase 2 clinical trial presented at this year’s AD/PD, along with previous clinical data, support the continued development of fosgonimeton. The encouraging pro-cognitive effects observed in the 40 mg dose group, assessed for fosgonimeton for the first time in Parkinson’s disease dementia and dementia with Lewy bodies, underscore our confidence in the Phase 2/3 LIFT-AD trial, which is evaluating fosgonimeton at 40 mg as a potential treatment for mild-to-moderate Alzheimer’s disease, with data expected in the second half of 2024.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ATHA:
- Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
- Athira Pharma Launches New Equity Incentive Plan for Talent
- Athira Pharma reports FY23 EPS ($3.09), consensus ($3.33)
- Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
- 2 “Strong Buy” Penny Stocks That Could Rally All the Way to $10 (or More)
Questions or Comments about the article? Write to editor@tipranks.com